Investing.com - Novartis ADR reported on Tuesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Novartis ADR announced earnings per share of $1.56 on revenue of $12.78B. Analysts polled by Investing.com anticipated EPS of $1.52 on revenue of $12.93B.
Novartis ADR shares are down 5.45% from the beginning of the year, still down 13.10% from its 52 week high of $95.17 set on August 17, 2021. They are under-performing the EUR/USD which is down 0% from the start of the year.
Novartis ADR follows other major Healthcare sector earnings this month
Novartis ADR's report follows an earnings beat by UnitedHealth on Friday, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
Roivant Sciences had beat expectations on June 28 with first quarter EPS of $-0.2711 on revenue of $9.22M, compared to forecast for EPS of $-0.3167 on revenue of $11.43M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar